And this effect from the PPAR-gamma ligands on gastric cancer cells, activate PPAR-gamma in a variety of tissues and cancer cells, and the ligand, the PPAR – PPAR are a novel treatment a novel treatment manifested. Assigned to the PPAR-gamma ligand generally decreases the survival rate of cancer cells through differentiation, apoptosis induction, and changes in the genes or proteins with admission to the G1 / S phase. It has been reported, suggesting that gastric cancer cells manifest PPAR-gamma and are suppressed by the PPAR-gamma ligand pre mature ejackulation . Recently it was shown that another report troglitazone, the ligand of PPAR-gamma may be useful in preventive medicine, and this effect is dependent on PPAR-gamma.
With respect to clinical applications, this could be an alternative method of intravenous injection of stem cells, which is not induced stable chimerism in the recipient, unless after a heavy conditioning therapy.
Non-invasive to premature may can be delayed by iron deficient to Womb.